Exosome Development and Manufacturing Services Market, 2022-2035

Exosome Development and Manufacturing Services Market, 2022-2035

Exosomes are extracellular vesicles that play an important role in cell-to-cell communication and act as carriers of circulating nucleic acids, lipids and proteins in body. Over time, various research studies have demonstrated the potential of exosomes in disease diagnosis and drug delivery applications, owing to their ability to act as biomarkers for various diseases and transport important functional elements. Given the various benefits, exosomes have gained significant interest in the biopharmaceutical industry, likely to result in their increased demand. However, the development and manufacturing of exosomes is associated with several challenges, including lack of standardized isolation and purification methods, limited drug loading ability, and inadequate clinical grade production and GMP compliant industrial scale-up. Therefore, outsourcing of exosome development and manufacturing is seen as a preferable option by companies focused on development of exosome based diagnostics and therapeutics.

Presently, several companies offer services for exosome development and manufacturing. The primary benefit of engaging service providers is to overcome various challenges related to exosome development, such as heterogeneity of exosomes, optimization of exosome isolation, purification and characterization methods and lack of specific biomarkers. Further, in order to leverage the full potential of exosomes, advanced exosome technologies are being developed to fully substructure their therapeutic applications. In addition, extensive research is being conducted to develop methods for extraction of exosomes with high level of purity and sensitivity. The growth in research over the last few years is evident from the published scientific literature and the clinical trial activity in this domain. The market has also witnessed substantial partnership activity, including several technology licensing deals. Moreover, the service providers are actively upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for these extracellular vesicles. Driven by the ongoing research activity, technological advancements and efforts of the players offering exosome development and manufacturing services, the market is poised to witness healthy growth over the next decade.

SCOPE OF THE REPORT

The “Exosome Development and Manufacturing Services Market by Scale of Operation (Discovery / Research, Preclinical and Clinical) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely future potential of exosome service providers over the next decade. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this field. In addition to other elements, the report includes:

A detailed assessment of the current market landscape of exosome service providers along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).

A competitiveness analysis of exosome service providers based on various relevant parameters, such as supplier strength (based on the experience / expertise of the service providers and company size), service strength (number of stages of development (discovery, preclinical, clinical or commercialized), scalability criteria, number of isolation and purification methods, number of characterization methods, number of chromatography techniques, quality control methods and exosome manufacturing methods).

Detailed profiles of prominent exosome service providers. Each company profile features a brief overview of the company, its financial information (if available), details on its exosome service portfolio, recent developments and an informed future outlook.

An analysis of the partnerships that have been established in this domain since 2016, covering R&D agreements, research, development and commercialization collaborations, product development agreements, mergers and acquisitions, product development and commercialization agreements, distribution / supply agreements, licensing deals, asset acquisitions, and clinical trial agreements.

A detailed review of 6,451 peer-reviewed, scientific articles related to research on exosomes on the basis of several relevant parameters, such as year of publication, type of service(s) offered, emerging focus areas. The chapter also highlights the top journals (in terms of number of articles published and impact factor).

A detailed analysis of the global events attended by the participants, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events). The chapter also highlights the geographical mapping of upcoming events.

An overview of the landscape of exosome-based technologies, featuring analyses of various technology providers, based on several relevant parameters, such as year of establishment, company size and location of headquarters.

An insightful analysis of the patents filed / granted for exosome technologies, during the period between 2016 and 2021 (till November), taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus areas, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent benchmarking, patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.

A detailed analysis of completed and ongoing clinical trials of exosomes, based on different parameters, such as trial status, trial registration year, trial registration year and enrolled patient population, trial recruitment status, trial phase and number of patients enrolled, study design, type pf sponsor / collaborator, leading players (on basis of number of registered trials),emerging focus areas and location of the trials (on basis of number of registered trials and enrolled patient population).

One of the key objectives of the report was to evaluate the existing market size, primary growth factors and opportunity within the exosome development and manufacturing services market in the mid to long term. Our year-wise projections of the current and future opportunity within the exosome development and manufacturing services market have further been segmented across [A] scale of operation (discovery / pre-clinical stage and clinical stage) [B] key geographies (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the anticipated industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

Jonathan Carson (Strategic Marketing Manager, EVerZom)

Navdeep Singh (Product Manager and Technical Lead, Clara Biotech)

Nicolas Rousseau (Chief Compliance Officer and Co-founder, RoosterBio)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

1. Annual reports

2. Investor presentations

3. SEC filings

4. Industry databases

5. News releases from company websites

6. Government policy documents

7. Industry analysts’ views

While the focus has been on forecasting the market till 2035, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

Who are the leading players offering exosome related services?

Which are the various technology platforms available in the market for the development of exosomes?

What is the relative competitiveness of different exosome service providers?

What kind of partnership models are commonly adopted by industry and non-industry stakeholders?

What is the focus area of the ongoing research activities related to exosomes?

How has the intellectual property landscape of exosomes evolved over the years?

What are the key agenda items being discussed in various global events / conferences related to exosomes?

Which companies are actively involved in conducting clinical trials for exosomes?

How is the current and future market opportunity related to exosomes, likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the current status of exosome development and manufacturing services market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to exosomes, types of extracellular vesicles and composition of exosomes. Further, the chapter presents details on the various therapeutic applications of exosomes, advantages and challenges associated with the development and manufacturing of exosomes along with the future perspectives. In addition, the chapter provides information on the isolation, characterization, manufacturing and outsourcing of exosome related services.

Chapter 4 includes information on more than 45 exosome service providers that are currently offering services related to exosomes, and a detailed analysis based on several parameters, such as types of service(s) offered, method of isolation, method of purification, method of characterization, method of exosome manufacturing, scale of operation and scalability. In addition, it provides details on the companies along with information on their year of establishment, company size and location of headquarters.

Chapter 5 provides a competitiveness analysis of exosomes service providers based on various relevant parameters, such as supplier strength (based on the experience / expertise of the service providers and company size), service strength (number of stages of development, scalability criteria, number of isolation and purification methods, number of characterization methods, number of chromatography techniques, quality control methods and exosome manufacturing methods).

Chapter 6 includes detailed profiles of prominent players offering exosome related services. Each profile features a brief overview of the company, its financial information (if available), details on its exosome service portfolio, recent developments and an informed future outlook.

Chapter 7 features an insightful analysis of the partnerships that have been established in this domain, during the period between 2016 and 2021 (till November)., covering R&D agreements, research, development and commercialization collaborations, product development agreements, mergers and acquisitions, product development and commercialization agreements, distribution / supply agreements, licensing deals, asset acquisitions, and clinical trial agreements.

Chapter 8 features a detailed review of peer-reviewed, scientific articles related to research on exosomes, on the basis of several relevant parameters, such as year of publication, type of service(s) offered, emerging focus areas. The chapter also highlights the top journals (in terms of number of articles published and impact factor).

Chapter 9 features an analysis of the global events attended by the service providers, based on several parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participant, active speakers (in terms of number of events). The chapter also highlights the geographical mapping of upcoming events.

Chapter 10 presents an overview of the landscape of exosome-based technologies, featuring analyses of various technology providers, based on several relevant parameters, such as year of establishment, company size and location of headquarters.

Chapter 11 provides an insightful analysis of the patents filed / granted for exosomes during the period between 2016 and 2021 (till November) taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical location, Cooperative Patent Classification (CPC) symbols, emerging focus area, leading industry and non-industry players (on the basis of number of patents) and individual patent assignees (in terms of size of intellectual property portfolio), patent benchmarking, patent characteristics and age of patents. The chapter also includes an insightful valuation analysis.

Chapter 12 provides information on completed and ongoing clinical studies of exosomes, based on different parameters, such as trial status, trial registration year, trial registration year and enrolled patient population, trial recruitment status, trial phase and number of patients enrolled, study design, type pf sponsor / collaborator, leading players (on basis of number of registered trials), emerging focus areas and location of the trials (on basis of number of registered trials and enrolled patient population).

Chapter 13 features an insightful market forecast analysis, highlighting the likely growth of the exosome development and manufacturing services market, till the year 2035. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] scale of operation (discovery / pre-clinical stage and clinical stage) [B] key geographies (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 14 summarizes the entire report, highlighting various facts related to contemporary market trend and the likely evolution of the exosome development and manufacturing services market.

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. In this chapter, we have presented detailed transcripts of interviews held with (in alphabetical order) Jonathan Carson (Strategic Marketing Manager, RoosterBio), Navdeep Singh (Product Manager and Technical Lead, Clara Biotech) and Nicolas Rousseau (Chief Compliance Officer and Co-founder, EVerZom).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.